NASDAQ:OPGNOpGen Stock Price, Forecast & News

OpGen's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OPGN stock has decreased by 4.3% and is now trading at $1.98. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OpGen.

OpGen is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for OpGen.

OpGen Inc (NASDAQ:OPGN) issued its earnings results on Thursday, May, 7th. The medical research company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.14. The medical research company had revenue of $0.62 million for the quarter. OpGen had a negative net margin of 405.10% and a negative return on equity of 241.40%. View OpGen's earnings history.

Shares of OpGen reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen issued an update on its first quarter 2020 Pre-Market earnings guidance on Tuesday, April, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $617K - 617K, compared to the consensus revenue estimate of $800K.

1 equities research analysts have issued 12 month target prices for OpGen's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate OpGen's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 910.1% from the stock's current price. View analysts' price targets for OpGen.

News coverage about OPGN stock has been trending negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. OpGen earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutOpGen.

OpGen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 509,600 shares, an increase of 7.4% from the April 30th total of 474,600 shares. Based on an average daily volume of 2,530,000 shares, the short-interest ratio is currently 0.2 days. Currently, 5.0% of the shares of the company are sold short. View OpGen's Current Options Chain.

Some companies that are related to OpGen include Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), Biocept (BIOC), Psychemedics (PMD), PotNetwork (POTN), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Agile Therapeutics (AGRX), Energy Transfer LP Unit (ET), Protalix Biotherapeutics (PLX), Inovio Pharmaceuticals (INO), vTv Therapeutics (VTVT), Vaxart (VXRT), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

OpGen's stock is owned by many different retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (0.13%), Jane Street Group LLC (0.09%) and UBS Group AG (0.09%). Company insiders that own OpGen stock include Evan/ Fa Jones and NV In Liquidation Curetis. View institutional ownership trends for OpGen.

OPGN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jane Street Group LLC, and UBS Group AG. View insider buying and selling activity for OpGen.

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPGN stock can currently be purchased for approximately $1.98.

OpGen has a market capitalization of $29.84 million and generates $3.50 million in revenue each year. The medical research company earns $-12,450,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis. OpGen employs 44 workers across the globe.

The official website for OpGen is www.opgen.com.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]